





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 413/10, A61K 31/38, 31/42</p>	A1	<p>(11) International Publication Number: WO 99/29688</p> <p>(43) International Publication Date: 17 June 1999 (17.06.99)</p>											
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/US98/24526</p> <p>(22) International Filing Date: 23 November 1998 (23.11.98)</p> <p>(30) Priority Data:</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%;">60/067,830</td> <td style="width: 30%;">5 December 1997 (05.12.97)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>60/089,498</td> <td>16 June 1998 (16.06.98)</td> <td>US</td> </tr> <tr> <td>60/100,185</td> <td>14 September 1998 (14.09.98)</td> <td>US</td> </tr> </table> <p>(71) Applicant (for all designated States except US): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): POEL, Toni-Jo [US/US]; 304 Anderson, Wayland, MI 49348 (US). MARTIN, Joseph, P., Jr. [US/US]; 6749 North 32nd Street, Richland, MI 49093 (US). BARBACHYN, Michael, R. [US/US]; 32 Viola Drive, East Hampton, CT 06424 (US).</p> <p>(74) Agent: YANG, Lucy, X.; Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001 (US).</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published</p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> </td> </tr> </table>			<p>(21) International Application Number: PCT/US98/24526</p> <p>(22) International Filing Date: 23 November 1998 (23.11.98)</p> <p>(30) Priority Data:</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%;">60/067,830</td> <td style="width: 30%;">5 December 1997 (05.12.97)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>60/089,498</td> <td>16 June 1998 (16.06.98)</td> <td>US</td> </tr> <tr> <td>60/100,185</td> <td>14 September 1998 (14.09.98)</td> <td>US</td> </tr> </table> <p>(71) Applicant (for all designated States except US): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): POEL, Toni-Jo [US/US]; 304 Anderson, Wayland, MI 49348 (US). MARTIN, Joseph, P., Jr. [US/US]; 6749 North 32nd Street, Richland, MI 49093 (US). BARBACHYN, Michael, R. [US/US]; 32 Viola Drive, East Hampton, CT 06424 (US).</p> <p>(74) Agent: YANG, Lucy, X.; Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001 (US).</p>	60/067,830	5 December 1997 (05.12.97)	US	60/089,498	16 June 1998 (16.06.98)	US	60/100,185	14 September 1998 (14.09.98)	US	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published</p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(21) International Application Number: PCT/US98/24526</p> <p>(22) International Filing Date: 23 November 1998 (23.11.98)</p> <p>(30) Priority Data:</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%;">60/067,830</td> <td style="width: 30%;">5 December 1997 (05.12.97)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>60/089,498</td> <td>16 June 1998 (16.06.98)</td> <td>US</td> </tr> <tr> <td>60/100,185</td> <td>14 September 1998 (14.09.98)</td> <td>US</td> </tr> </table> <p>(71) Applicant (for all designated States except US): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): POEL, Toni-Jo [US/US]; 304 Anderson, Wayland, MI 49348 (US). MARTIN, Joseph, P., Jr. [US/US]; 6749 North 32nd Street, Richland, MI 49093 (US). BARBACHYN, Michael, R. [US/US]; 32 Viola Drive, East Hampton, CT 06424 (US).</p> <p>(74) Agent: YANG, Lucy, X.; Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001 (US).</p>	60/067,830	5 December 1997 (05.12.97)	US	60/089,498	16 June 1998 (16.06.98)	US	60/100,185	14 September 1998 (14.09.98)	US	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published</p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>			
60/067,830	5 December 1997 (05.12.97)	US											
60/089,498	16 June 1998 (16.06.98)	US											
60/100,185	14 September 1998 (14.09.98)	US											
<p>(54) Title: S-OXIDE AND S,S-DIOXIDE TETRAHYDROTHIOPYRAN PHENYLOXAZOLIDINONES</p> <div style="display: flex; justify-content: space-around; align-items: center; margin-top: 20px;"> <div style="text-align: center;">  <p>(I)</p> </div> <div style="text-align: center;">  <p>(II)</p> </div> </div> <p>(57) Abstract</p> <p>The present invention provides compounds of formula (I) and formula (II) useful as antimicrobial agents wherein R₁ is methyl, ethyl, cyclopropyl, or dichloromethyl; R₂ and R₃ are independently hydrogen or fluoro; R₄ is ethyl or dichloromethyl. The invention also relates to a novel assay for determining the inhibitory activity of oxazolidinones to human monoamine oxidase.</p>													

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

S-OXIDE AND S,S-DIOXIDE TETRAHYDROTHIOPYRAN
PHENYLOXAZOLIDINONES

FIELD OF THE INVENTION

5 The present invention relates to sulfur oxidized tetrahydrothiopyran
N-phenyloxazolidinone compounds in which the phenyloxazolidinone moiety is
linked with a thiopyran ring through a carbon-carbon bond. The invention also
relates to a novel assay for determining the inhibitory activity of oxazolidinones to
human monoamine oxidase.

10

BACKGROUND OF THE INVENTION

 The oxazolidinone antibacterial agents are a novel synthetic class of
antimicrobials with potent activity against a number of human and veterinary
pathogens, including gram-positive aerobic bacteria such as multiply-resistant
15 staphylococci and streptococci, gram-negative aerobic bacteria such as *H. influenzae*
and *M. catarrhalis*, as well as anaerobic organisms such as bacteroides and
clostridia species, acid-fast organisms such as *Mycobacterium tuberculosis* and
Mycobacterium avium. It is also known that as a chemical compound class,
oxazolidinones inhibit monoamine oxidase (MAO), the enzyme responsible for
20 preventing acute blood pressure elevation by the endogenous and dietary amine,
tyramine. Accordingly, there is a demand to discover oxazolidinone antibiotics
which possess minimum MAO inhibitory activity to eliminate the related side effects
from potential drug-drug interactions. There is also currently an interest in
developing a high throughput screening assay to determine the MAO inhibitory
25 activity of oxazolidinone antibiotics.

INFORMATION DISCLOSURE

 International Publication No. WO 97/09328; pending U.S. application, Serial
No. 08/696,313, discloses phenyloxazolidinones having a C-C bond to 4-8 membered
30 heterocyclic rings, which generically covers the compounds of the present
application.

 International Publication No. WO 97/30995 discloses antibiotic oxazolidinone
derivatives.

 Other references that disclose aromatic heterocycles attached to a
35 phenyloxazolidinone include European Patent Publication No. 0352 781 A2,
International Publication No. WO 9309103-A1 and U.S. Patent Nos. 5,130,316,


5,254,577 and 4,948,801.

Additional references of general interest include: Castagnoli Jr. et al.,
 Synthesis and Elective Monoamine Oxidase B-Inhibiting Properties of 1-Methyl-
 1,2,3,6-Tetrahydropyrid-4-yl Carbamate Derivatives: Potential Prodrugs of (R)- and
 5 (S)-Nordeprenyl, *J. Med. Chem.*, Vol. 39, pp. 4756-4761 (1996); Walter Weyler and J.
 I. Salach, "Purification and Properties of Mitochondrial Monoamine Oxidase Type A
 from Human Placenta", *J. of Bio. Chem.*, Vol. 260, No. 24, pp. 13199-13207 (1985)
 (10/25/85). J. I. Salach and Walter Weyler, Preparation of the Flavin-Containing
 Aromatic Amine Oxidases of Human Placenta and Beef Liver, *Methods Enzymol.*,
 10 Vol. 142, pp 627-623 (1987); Joseph J. P. Zhou, et al., "Direct Continuous
 Fluorometric Assay for Monoamine Oxidase B", *Analytical Biochemistry*, Vol. 234,
 pp. 9-12 (1996); Matthew J. Krueger, et al., "An Examination of the Reliability of the
 Radiochemical Assay for Monoamine Oxidases A and B", *Analytical Biochemistry*,
 Vol. 214, pp. 116-123 (1993); Keith F. Tipton, et al., "Commentary - The
 15 Radiochemical Assay for Monoamine Oxidase Activity - Problems and Pitfalls",
Biochemical Pharmacology, Vol. 46, No. 8, pp. 1311-1316 (1993).

SUMMARY OF THE INVENTION

In one aspect, the present invention is a compound of formula I

20



25


I

or pharmaceutically acceptable salts thereof wherein R₁ is methyl, ethyl, cyclopropyl,
 or dichloromethyl; R₂ and R₃ are the same or different and are
 hydrogen or fluoro. The formula I of the invention embraces both *trans*- and *cis*-
 isomers.

30

In another aspect, the present invention is a compound of formula II

35



II

or pharmaceutically acceptable salts thereof wherein R_2 and R_3 are the same as defined above; R_4 is ethyl or dichloromethyl.

Preferably, in the above formula I, R_1 is methyl or ethyl.

Preferably, in the above formula II, R_4 is ethyl.

5 Also preferably, compounds of formulas I and II are mono-fluoro compounds.

Preferred compounds of the present invention are:

- a. [4(S)-cis]-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- b. [4(S)-cis]-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]propionamide,
- 10 c. [4(S)-cis]-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropanecarboxamide,
- d. [4(S)-cis]-2,2-Dichloro-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- 15 e. (S)-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]propionamide,
- f. (S)-(-)-2,2-Dichloro-N-[[3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- g. [4(S)-trans]-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]propionamide,
- 20 h. [4(S)-trans]-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropanecarboxamide, or
- i. [4(S)-trans]-2,2-Dichloro-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

25 More preferred is compound [4(S)-cis]-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

In still another aspect, the present invention provides a method of assaying an oxazolidinone antibiotic's MAO inhibitory activity, which comprises the steps of

- a) incubating an oxazolidinone with a monoamine oxidase in a buffer
- 30 solution having pH value from about 7.0 to about 7.5;
- b) adding 1-methyl-4-(1-methyl-2-pyrrolyl)-1,2,3,6-tetrahydropyridine into said incubating solution; and
- c) determining the monoamine oxidase inhibitory activity of said oxazolidinone.

35

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides sulfur oxidized tetrahydrothiopyran phenyloxazolidinone of formula I and formula II as defined above. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens as disclosed above. In particular, it has been discovered that, while
5 oxazolidinones as a chemical compound class are inhibitors of human monoamine oxidase A (MAO A) and monoamine oxidase B (MAO B), the compounds of the present invention have unexceptedly weak MAO inhibitory activity, which indicates that these compounds possess the capacity to minimize or eliminate potential drug-drug interactions since strong inhibition of monoamine oxidase can result in
10 altered clearance rates for other compounds normally metabolized by it, including several pharmaceuticals.

The present invention also provides a novel spectrophotometric assay for determining the ability of an oxazolidinone to inhibit human monoamine oxidases. MAO A and MAO B are membrane bound flavoproteins localized in the outer
15 mitochondrial membrane. The two enzymes prefer different substrate in catalyzing the oxidative deamination of biogenic and xenobiotic amines. Historically, MAO enzymes have been assayed by radioactive end point (discontinuous) methods using two different substrates. These methods have been criticized because as commonly practiced, they lack the proof of linearity of the reaction time course under
20 prevailing assay conditions. The use of these methods are also inadequate due to their cumbersome nature when screening a large number of compounds in a short period of time. The methods involve multiple processing steps including solvent extraction of reaction products. These steps lead to inaccuracies in the resulting data. See: Matthew J. Krueger, et al., "An Examination of the Reliability of the
25 Radiochemical Assay for Monoamine Oxidases A and B", *Analytical Biochemistry*, Vol. 214, pp. 116-123 (1993); Keith F. Tipton, et al., "Commentary - The Radiochemical Assay for Monoamine Oxidase Activity - Problems and Pitfalls", *Biochemical Pharmacology*, Vol. 46, No. 8, pp. 1311-1316 (1993).

We have now developed a continuous, visible, high throughput screening
30 spectrophotometric assay of MAO based on a colored product of oxidation of a chromogenic substrate, 1-methyl-4-(1-methyl-2-pyrrolyl)-1,2,3,6-tetrahydropyridine. The assay works equally well with MAO-A and MAO-B. It is sensitive, linear and tolerant of the low turbidity level introduced by the solubilized and partially purified MAO A and MAO B. The reaction product is stable for many hours and the reaction
35 rates for both enzymes are linear functions of time and enzyme concentration. The assay has been successfully adapted to a microtiterplate format, therefore, it can

provide information on thousands of tested oxazolidinone compounds in a short period of time. Even in the microtiterplate screening format, accurate information concerning the linearity of the reaction rate under prevailing assay conditions is obtained.

- 5 In addition, while evaluation of oxazolidinone compounds' MAO inhibitory activity is the most important utility of this assay, the present invention can be used to detect any inhibitor of MAO enzymes.


For the purpose of the present invention, the term "pharmaceutically acceptable salts" refers to salts useful for administering the compounds of this invention and include hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, 10 acetate, propionate, lactate, mesylate, maleate, malate, succinate, tartrate, citrate, 2-hydroxyethyl sulfonate, fumarate and the like. These salts may be in hydrated form.

- Compounds of the present invention may be prepared in accordance to Schemes I and II following methodology known to those skilled in the art. Briefly, 15 as shown in Scheme I, hydrolysis of the N-acetyl oxazolidinone 1 with hydroxylamine hydrochloride, for instance, provides the amine 2. Treatment of structure 2 with an acid chloride or anhydride in the presence of a base affords N-acyl oxazolidinone 3, wherein n is 1 or 2, and R is R₁ or R₄ as defined above.
- 20 Structure 1 in which n is 2 can be obtained according to the procedures disclosed in International Publication No. WO 97/09328; structure 1 in which n is 1 can be prepared as shown in Scheme II.


- Compound 4 in Scheme II, which can be obtained according to the procedures disclosed in International Publication No. WO 97/09328, may be reduced to the 25 corresponding cis- and trans-sulfoxides 6 and 7 by catalytic hydrogenation in the presence of an appropriate catalyst and a suitable solvent, as depicted in route a. Alternatively, sulfide 5, which may be isolated as a by-product in the reduction shown in route a or synthesized by the reduction of 6 or 7 with a sulfonic acid-sodium iodide system, can be oxidized with an appropriate oxidizing agent such 30 NaIO₄ or meta-chloroperoxybenzoic acid in an appropriate solvent to provide 6 and 7, as depicted in route b of Scheme II. The isomeric mixture of 6 and 7 can be separated by chromatography.

SCHEME I


5




10



15



SCHEME II



These compounds are useful for the treatment of microbial infections, including ophthalmologic infections, in humans and other warm blooded animals, under both parental and oral administration.

The pharmaceutical compositions of this invention may be prepared by combining the compounds of Formulas I and II of this invention with a solid or liquid pharmaceutically acceptable carrier and, optionally, with pharmaceutically acceptable adjuvants and excipient employing standard and conventional techniques. Solid form compositions include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent. Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like. Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water and water-propylene glycol and water-polyethylene glycol

systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.

Preferably, the pharmaceutical composition is provided employing conventional techniques in unit dosage form containing effective or appropriate amounts of the active component, that is, the compounds of formula I or II according to this invention.

The quantity of active component, that is the compound of formula I or II according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application, the potency of the particular compound and the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.

In therapeutic use for treating, or combatting, bacterial infections in warm-blooded animals, the compounds or pharmaceutical compositions thereof will be administered orally, topically, transdermally, and/or parenterally at a dosage to obtain and maintain a concentration, that is, an amount, or blood-level of active component in the animal undergoing treatment which will be antibacterially effective. Generally, such antibacterially effective amount of dosage of active component will be in the range of about 0.1 to about 100, more preferably about 3.0 to about 50 mg/kg of body weight/day. It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of the bacterial infection being treated, and the particular compound being used. Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., two to four times per day.

The compounds of formulas I and II according to this invention are administered parenterally, i.e., by injection, for example, by intravenous injection or by other parenteral routes of administration. Pharmaceutical compositions for parenteral administration will generally contain a pharmaceutically acceptable amount of the compound according to formula I or II as a soluble salt (acid addition salt or base salt) dissolved in a pharmaceutically acceptable liquid carrier such as, for example, water-for-injection and a buffer to provide a suitably buffered isotonic solution, for example, having a pH of about 3.5-6. Suitable buffering agents include,

for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine to name but a few representative buffering agents. The compounds according to formula I or II generally will be dissolved in the carrier in an amount sufficient to provide a pharmaceutically acceptable injectable concentration in the range of about 1 mg/ml to about 400 mg/ml of solution. The resulting liquid pharmaceutical composition will be administered so as to obtain the above-mentioned antibacterially effective amount of dosage. The compounds of formulas I and II according to this invention are advantageously administered orally in solid and liquid dosage forms.

10 The oxazolidinone antibacterial agents of this invention have useful activity against a variety of organisms. The in vitro activity of compounds of this invention can be assessed by standard testing procedures such as the determination of minimum inhibitory concentration (MIC) by agar dilution as described in "Approved Standard. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That
15 Grow Aerobically", 3rd. ed., published 1993 by the National Committee for Clinical Laboratory Standards, Villanova, Pennsylvania, USA. The activity of compounds of this invention against *Staphylococcus aureus* and *H. influenzae* is shown in Table 1.

 The continuous spectrophotometric assay for measuring MAO activity is based on a colored oxidation product of the chromogenic substrate, 1-methyl-4-(1-methyl-2-pyrrolyl)-1,2,3,6-tetrahydropyridine, by MAO enzymes. The product is stable
20 for many days at room temperature. The conversion of the substrate to the oxidation product is followed continuously from the moment of mixing of the MAO enzyme with the substrate and the initial reaction rate curve is directly observed. The bright yellow-green oxidation product has a peak absorption at 421 nm with a
25 broad band that can be measured between 390 nm to 440 nm. Thus, the assay can be performed on the least sophisticated spectrophotometric equipment. The substrate itself is colorless; and does not spontaneously convert to product under conditions of the assay; thus, there is no interfering background rate.

 The assay is sensitive, which allows accurate rate measurements at very low
30 levels of change in the substrate concentration (<1%). The sensitivity of the assay permits measurements to be made on very low concentrations of the MAO enzymes, whether pure or in tissue homogenates. The assay is not susceptible to background interference from biologically derived materials all of which absorb between 210-350 nm.

35 The assay shows a linear reaction rate over a wide range of MAO enzymes, of the substrate, and of oxazolidinones concentrations and over a considerable portion

of the progress curve at any substrate or enzyme concentration. For example, the assay shows a linear reaction rate at final oxazolidinone's concentration from about 1 mM to about 1 nM; at any concentration of the enzymes which is sufficient to produce an absorbance change of 0.0005-0.05/minute at 421 nm; and at the substrate's concentration from about 10 μ M to about 10 mM. The reaction rate is also linear over long time intervals (up to 90 minutes) even at low enzyme concentrations. These properties permit a highly accurate rate determination as a function of substrate concentration, enzyme concentration or oxazolidinone inhibitor concentration.

The assay may be carried out in a buffer solution which does not adversely affect the reaction and provides a pH value at a range from about 7.0 to 7.5. The preferred buffer solution is sodium phosphate. The preferred pH value for assay is about 7.3. Further, the assay is preferably conducted at a temperature from about 25 °C to about 40 °C. The most preferred assay temperature is about 37 °C.

The chromogenic substrate 1-methyl-4-(1-methyl-2-pyrrolyl)-1,2,3,6-tetrahydropyridine can be prepared as described in N. Castagnoli Jr. et al., *J. Med Chem.*, Vol. 39, pp. 4756-4761 (1996) and the references cited within. The substrate is prepared as a 10-15 mM stock solution in 50 mM sodium phosphate. The solution is kept on ice or frozen and are typically diluted 1/10-1/100 by 50 mM sodium phosphate (pH = 7-7.5) at the time of assay.

Human placental MAO A is solubilized and purified as described in N. Castagnoli Jr. et al., *J. Med Chem.* Vol. 39, pp. 4756-4761 (1996) and J. I. Salach et al., *J. of Bio. Chem.*, Vol. 260, p. 13199 (1985). The human placental MAO A is obtained as a concentrated solution (5 nmols per ml). Bovine liver MAO B is purified as described N. Castagnoli Jr. et al., *J. Med Chem.*, Vol. 39, pp. 4756-4761 (1996) and J. I. Salach et al., *Methods Enzymol.*, Vol. 142, pp 627-623 (1987). The bovine liver MAO B is obtained as a concentrated solution (8 nmols per ml). Working stocks of the enzyme solutions are made by 1/50 dilution of initial stocks into 50 mM sodium phosphate and optionally 10% glycerol. The solutions are kept on ice until final dilution into the assay. Alternatively, the frozen MAO enzymes may be diluted 800-3200 fold into the 50 mM sodium phosphate buffer immediately before use. This method is useful when screening a large number of oxazolidinones.

Oxazolidinones are prepared in DMSO at a concentration of 50 mM. Serial dilutions of the 50 mM stock solution are made in DMSO to form additional stock solutions ranging from 20 mM to 0.3125 mM. The stock solutions are then frozen until use. The stocks are diluted 1/100 into the final enzyme assay volume at the

time of assay.

Typically, the enzyme, along with an oxazolidinone inhibitor, are preincubated for approximately 15 minutes in the sodium phosphate buffer prior to assay. The reactions are started by addition of the substrate. Initial velocities are
5 generally collected over an interval of one to sixty minutes.

The assay functions well in the spectrophotometer cuvette for evaluating single oxazolidinone's MAO inhibitory activity. The assay has also been successfully adapted to operate in high throughput microtiterplate format (i.e., 96, 384 and 1536 well plate readers). Hundreds of assays can be run simultaneously. Assay volumes
10 are 250 μ L and the wells have an effective path length of 0.75 cm. Generally, the final composition of the assay in the microtiterplate comprises 0.05 mM sodium phosphate (pH = 7.3), oxazolidinone having concentration ranging up to 500 μ M, 1% DMSO, 80 μ M substrate (MAO A) or 200 μ M substrate (MAO B), and sufficient enzyme to produce an absorbance change from 0.0005 to 0.050 per minute at 421
15 nm. The reaction is run at 37 °C, and rapid temperature equilibration of the assay solution is achieved by preincubating the plate and stock solutions at about 37 °C. The reaction is followed by recording the increase in absorbance at 421 nm. The oxidation product has an extinction coefficient of 25,000 $M^{-1} cm^{-1}$ at 420. See: N. Castagnoli Jr. et al., *J. Med Chem.*, Vol. 39, pp. 4756-4761 (1996). Initial rates are
20 determined by linear regression of the progress curves over an absorbance change of 0.06-0.12 at 421 nm. This range represents a substrate consumption of approximately 5% in the assay. The percentage inhibition of an oxazolidinone is determined from the following equation

$$\begin{aligned} 25 \quad \% \text{ Inhibition} = & 100 \{ 1 - [\text{rate(I)} - \text{rate (negative control)}] / \\ & [\text{rate (positive control)} - \text{rate (negative control)}] \} \end{aligned}$$

In the above equation, the term "negative control" refers to a complete assay with 1% of DMSO but no MAO enzyme. The term "positive control" refers to a
30 complete assay with 1% of DMSO but no inhibitor. The term "rate (I)" refers to the reaction rate under a complete assay conditions. The term "rate (negative control)" refers to the reaction rate under the negative control condition. The term "rate (positive control)" refers to the reaction rate the under position control condition. In the case where a single oxazolidinone's MAO inhibitory activity is evaluated in the
35 microtiterplate screening format, two replicates of positive control assay and two replicates of negative control assay are run to produce averaged control rates. In


the case where microtiterplate format is used to derive an inhibitory constant (K_i) for an oxazolidinone inhibitor, each plate contains four to eight wells without inhibitor (positive control). These rates are averaged to produce the mean uninhibited control rate for the plate. Each inhibitor is tested at six to eight concentrations. Inhibitory percentage at each concentration is established relative to the uninhibited control rate. Since oxazolidinones are competitive inhibitors of MAO enzymes, the dissociation constant K_i is calculated from the initial velocity data using the following equation:

$$\% \text{Inhibition} = 100[I] / ([I] + K_i (1 + [S]/K_{m(s)}))$$

See I. H. Segel, *Enzyme Kinetics.*, Vol. 957, p.105, (1975). Wiley Interscience. NY, NY. In this equation, $[S]$ refers to the concentration of the chromogenic substrate; $[I]$ refers to the concentration of an oxazolidinone inhibitor; and $K_{m(s)}$ refers to the dissociation constant of the substrate for the MAO enzyme. In practice, the data points from the inhibitor experiment are fit to the equation by non-linear least squares regression analysis. The K_i parameter and its standard error are estimated by the regression procedure. A low K_i value indicates that the tested inhibitor possesses a tight binding ability to MAO enzyme, thus, it is a strong MAO inhibitor.

The compounds and their preparations of the present invention will be better understood in connection with the following examples, which are intended as an illustration of and not a limitation upon the scope of the invention.

EXAMPLE 1 Preparation of [4(S)-cis]-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.




A mixture of (S)-(-)-N-[[3-[3-fluoro-4-(3,6-dihydro-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide S-oxide (4.50 g, can be obtained according to the procedures disclosed in International Publication No. WO 97/09328) and platinum oxide (697 mg) in methanol (164 mL) is shaken on the Parr apparatus under a hydrogen atmosphere at 40 psi for 18 hours. The catalyst is then removed by

filtration through Celite, and the filtrate is concentrated under reduced pressure and the residue chromatographed on silica gel (230 - 400 mesh, 350 g), eluting with a gradient of methanol/methylene chloride (3/97 - 7/93). Pooling and concentration of those fractions with an $R_f = 0.44$ by TLC (methanol/chloroform, 10/90) gives the title
 5 compound, mp 203 - 204 °C.

EXAMPLE 2 Preparation of [4(S)-cis]-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]propionamide.

10



15 Step 1: Preparation of [4(S)-cis]-3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone.

A mixture of [4(S)-cis]-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (EXAMPLE 1, 2.50 g) and hydroxylamine hydrochloride (2.36 g) in pyridine (30.6 mL) and ethanol (3.4 mL) is
 20 stirred in a screw-cap vial at 100 °C for 22 hours and at ambient temperature for 16 hours, during which additional hydroxylamine hydrochloride (944 mg) and pyridine (4 mL) is added. The reaction mixture is then concentrated under reduced pressure, diluted with saturated aqueous sodium bicarbonate (100 mL) and saline (50 mL), adjusted to pH 11 with solid sodium carbonate and extracted with
 25 methanol/methylene chloride (10/90, 5 x 100 mL). The combined organic phase is concentrated under reduced pressure, and the crude product is chromatographed on silica gel (230 - 400 mesh, 150 g), eluting with a gradient of methanol/methylene chloride (6/94 - 10/90). Pooling and concentration of those fractions with an $R_f = 0.14$ by TLC (methanol/chloroform, 10/90) gives the title compound, mp 159 - 161 °C.


30 Step 2: Preparation of [4(S)-cis]-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]propionamide.

A solution of [4(S)-cis]-3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone (EXAMPLE 2, Step 1, 150 mg), propionic anhydride (62 µL) and pyridine (75 µL) in methylene chloride is stirred under a
 35 nitrogen atmosphere for 66 hours, during which time additional propionic anhydride (12 µL) is added. The reaction mixture is then diluted with water (15 mL) and

extracted with methylene chloride (2 x 20 mL), and the combined organic phase is washed with saline (10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product which is chromatographed on silica gel (230 - 400 mesh, 35 g), eluting with a gradient of methanol/methylene chloride (3/97 - 5/95). Pooling and concentration of those fractions with an $R_f = 0.51$ by TLC (methanol/chloroform, 10/90) and recrystallization from methylene chloride/diethyl ether gives the title compound, mp 212 - 214 °C (dec.).

EXAMPLE 3 Preparation of [4(S)-cis]-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl] cyclopropane-carboxamide.

15




A solution of [4(S)-cis]-3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone (EXAMPLE 2, Step 1, 250 mg) and triethylamine (0.16 mL) in methylene chloride (3.1 mL) at 0 °C under a nitrogen atmosphere is treated with cyclopropanecarbonyl chloride (73 µL) and stirred at 0 °C for 2 hours. The reaction mixture is then diluted with methylene chloride (25 mL), washed with water (10 mL) and saline (10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product which is chromatographed on silica gel (230 - 400 mesh, 40 g), eluting with methanol/methylene chloride (5/95). Pooling and concentration of these fractions with an $R_f = 0.65$ by TLC (methanol/chloroform, 10/90) followed by trituration with methylene chloride/diethyl ether (50/50) and filtration gives the title compound, mp 242 - 243 °C (dec.).

EXAMPLE 4 Preparation of [4(S)-cis]-2,2-dichloro-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

35

5




Following the general procedure of EXAMPLE 3, and making non-critical variations but substituting dichloroacetyl chloride for cyclopropanecarbonyl chloride, the title compound is obtained, mp 198 - 200 °C (dec.).

10

EXAMPLE 5 Preparation of (S)-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]propionamide.

15



Step 1: Preparation of (S)-(-)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone.

Following the general procedure of EXAMPLE 2, Step 1, and making non-critical variations but substituting (S)-(-)-N-[[3-[3-fluoro-4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide S,S-dioxide (can be obtained according to the procedures disclosed in International Publication No. WO 97/09328) for [4(S)-cis]-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, the title compound is obtained, mp 194 °C (dec.).

Step 2: (S)-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]propionamide


Following the general procedure of EXAMPLE 2, Step 2, and making non-critical variations but substituting (S)-(-)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone (EXAMPLE 5, Step 1) for [4(S)-cis]-3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone and allowing for a reaction time of 2 hours, the title compound is obtained, mp 200 - 201 °C.

35

EXAMPLE 6 Preparation of (S)-(-)-2,2-dichloro-N-[[3-[3-fluoro-4-(tetrahydro-

1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide.

5




Following the general procedure of EXAMPLE 3, and making non-critical variations but substituting dichloroacetyl chloride for cyclopropanecarbonyl chloride and (S)-(-)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone (EXAMPLE 5, Step 1) for [4(S)-cis]-3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone and chromatographing the crude product with methanol/chloroform (2/98), the title compound is obtained, mp 136-137 °C (dec.).

15

EXAMPLE 7 Preparation of [4(S)-trans]-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]propionamide.

20



25 Step 1: Preparation of (S)-(-)-N-[[3-[3-fluoro-4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide.

Following the general procedure of EXAMPLE 1, and making non-critical variations but pooling and concentrating those fractions from the chromatography with an $R_f = 0.67$ by TLC (methanol/chloroform, 10/90), the title compound is obtained, mp 202 - 205 °C. Anal. Calcd for $C_{17}H_{21}FN_2O_3S$: C, 57.94; H, 6.01; N, 7.95; S, 9.10. Found: C, 57.95; H, 5.98; N, 7.94; S, 8.97.

30 Step 2: Preparation of [4(S)-trans]-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide.

A slurry of (S)-N-[[3-[3-fluoro-4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide (EXAMPLE 7, Step 1, 2.50 g) in methylene chloride (35 mL) at 0 °C under a nitrogen atmosphere is treated with MCPBA (2.16 g, <85%

35

pure, <10.64 mmol) in two portions. The resulting mixture is allowed to warm to ambient temperature and is stirred for 20 hours, during which time additional MCPBA (360 mg, <85% pure, <1.77 mmol) is added. The reaction is then diluted with methylene chloride (50 mL) and washed with saturated aqueous sodium bicarbonate (50 mL), the aqueous phase is reextracted with methanol/methylene chloride (2 x 50 mL, 5/95), and the combined organic phase is washed with saline (25 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude reaction mixture is chromatographed on silica gel (230-400 mesh, 350 g), eluting with a gradient of methanol/methylene chloride (3.5/96.5 - 5/95), and those fractions with an $R_f = 0.42$ by TLC (methanol/chloroform, 10/90) are pooled and concentrated to give a mixture of the *cis* and *trans* sulfoxide products. Subsequent purification by HPLC (Chiralcel OD column, ethanol eluent) followed by trituration with methylene chloride/diethyl ether (50/50) gives the title compound, mp 211 - 212 °C.

15 Step 3: Preparation of [4(S)-*trans*]-(-)-3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone.


Following the general procedure of EXAMPLE 2, Step 1, and making non-critical variations but substituting [4(S)-*trans*]-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide for [4(S)-*cis*]-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, the title compound is obtained, mp 138 - 140 °C.

20 Step 4: Preparation of [4(S)-*trans*]-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]propionamide.

Following the general procedure of EXAMPLE 2, Step 2, and making non-critical variations but substituting [4(S)-*trans*]-(-)-3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone for [4(S)-*cis*]-(-)-3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone, the title compound is obtained, mp 200 - 202 °C (dec.).

30 EXAMPLE 8 Preparation of [4(S)-*trans*]-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropane-carboxamide.


5



Following the general procedure of EXAMPLE 3, and making non-critical variations but substituting [4(S)-trans]-(-)-3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone for [4(S)-cis]-(-)-3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone, the title compound is obtained, mp 189 - 191 °C.

EXAMPLE 9 Preparation of [4(S)-trans]-2,2-dichloro-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

20



Following the general procedure of EXAMPLE 3, and making non-critical variations but substituting dichloroacetyl chloride for cyclopropanecarbonyl chloride and [4(S)-trans]-(-)-3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone for [4(S)-cis]-(-)-3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone, the title compound is obtained, mp 206 - 208 °C (dec.).

EXAMPLE 10 Evaluation of Oxazolidinones' Inhibitory Activity to Human MAO-A

The solubilized and purified forms of human MAO-A and the substrate are obtained from Dr. Neal Castagnoli Jr's lab in Department of Chemistry, Virginia Technical University, Blacksburg, Virginia.

Preparation of buffer solutions: sodium phosphate was prepared as a 50 mM stock solution, pH = 7.3 at 37 °C. Preparation of the testing compounds: stock solutions (50 mM) of the test compounds were prepared in DMSO. Serial dilutions of

the 50 mM stocks were made in DMSO to form additional stock solutions ranging from 20 mM to 0.3125 mM. These stocks were then frozen until needed. The stocks were diluted 1/100 into the final enzyme assay volume at the time of assay. A 10 mM stock solution of the chromogenic substrate was prepared in the 50 mM phosphate buffer, aliquoted and then frozen until time of use.

Enzyme Assay- Initial velocity assays were run in a SPECTRAmax 250 microplate spectrophotometer (Molecular Devices Corp., Sunnyvale, CA.). The final composition of the assay solution comprises 0.05 M sodium phosphate (pH = 7.3), 80 μ M substrate, inhibitor concentrations ranging up to 500 μ M, 1% DMSO, and sufficient enzyme to produce an absorbance change at 421 nm of 0.0005-0.005/minute. The reactions were run at 37 °C. The reaction was followed by recording the increase in absorbance at 421 nm. Inhibitors were pre-incubated with the MAO A in the reaction mixture for 15 minutes prior to starting the reaction. K_i values were determined from the initial velocity data using the above equation.

The results are also shown in Table 1.

TABLE 1

In vitro activities against *S. aureus* UC® No. 9213 and gram-negative bacteria *H. influenzae* 30063, and inhibitory activity data of human MAO A.


5

10

Example No.	MIC (µg/mL) <i>S. aureus</i> (UC 9213)	MIC (µg/mL) H. <i>influenzae</i> 30063	Ki (µM)
1	4	8	648
2	8	16	>3000
3	8	16	734
4	2	8	2570
5	8	8	3000
6	2	8	>3000
7	4	4	905
8	2	16	>3000
9	1	2	396

CLAIMS

1. A compound of formula I



10

I

or pharmaceutically acceptable salts thereof wherein:

R₁ is


- 15
- a) methyl,
 - b) ethyl,
 - c) cyclopropyl, or
 - d) dichloromethyl;

R₂ and R₃ are the same or different and are

- a) hydrogen, or
- b) fluoro.


20

2. A compound of claim 1 wherein R₁ is methyl.
3. A compound of claim 1 wherein R₂ is fluoro; R₃ is hydrogen.
- 25 4. A compound of formula I in claim 1 which is



5. A compound of formula I in claim 1 which is
- 35


5



6. A compound of claim 1 which is
- [4(S)-cis]-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
 - 10 [4(S)-cis]-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]propionamide,
 - [4(S)-cis]-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropanecarboxamide,
 - d. [4(S)-cis]-2,2-Dichloro-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.
 - 15 e. [4(S)-trans]-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]propionamide,
 - f. [4(S)-trans]-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropanecarboxamide, or
 - 20 g. [4(S)-trans]-2,2-Dichloro-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

7. A compound of formula II

25



30

II

or pharmaceutically acceptable salts thereof wherein

R₂ and R₃ are the same or different and are

- a) hydrogen, or
- b) fluoro;

35 R₄ is

- a) ethyl, or

b) dichloromethyl.

8. A compound of claim 7 wherein R₂ is fluoro; R₃ is hydrogen.

5 9. A compound of claim 7 which is

a. (S)-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]propionamide, or

b. (S)-(-)-2,2-Dichloro-N-[[3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

10

10. A use of a compound of Formula I or pharmaceutically acceptable salts thereof for the preparation of a medicament to treat microbial infections in patients comprising:

administering to a patient in need thereof an effective amount of a compound of

15 Formula I as shown in claim 1.

11. A use of a compound of Formula II or pharmaceutically acceptable salts thereof for the preparation of a medicament for treating microbial infections in patients comprising:

20 administering to a patient in need thereof an effective amount of a compound of Formula II as shown in claim 7.

12. The use of claim 10 wherein said compound of Formula I is administered orally, parenterally, transdermally, or topically in a pharmaceutical composition.

25

13. The use of claim 11 wherein said compound of Formula II is administered orally, parenterally, transdermally, or topically in a pharmaceutical composition.

14. The use of claim 10 wherein said compound is administered in an amount of
30 from about 0.1 to about 100 mg/kg of body weight/day.

15. The use of claim 11 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

35 16. A method of assaying compounds which may have monoamine oxidase inhibitory activity comprising the steps of :

- a) incubating a potential inhibitor with a monoamine oxidase in a buffer solution having pH value from about 7.0 to about 7.5;
- b) adding 1-methyl-4-(1-methyl-2-pyrrolyl)-1,2,3,6-tetrahydropyridine into said incubating solution; and
- 5 c) determining the monoamine oxidase inhibitory activity of said oxazolidinone.
17. The method of claim 16 wherein said inhibitor is an oxazolidinone antibiotic.
- 10 18. The method of claim 16 wherein said buffer solution is a phosphate solution.
19. The method of claim 16 wherein the pH value of said buffer solution is about 7.3.
- 15 20. The method of claim 16 wherein the length of incubation is about 15 minutes.
- 21 The method of claim 16 wherein said monoamine oxidase is monoamine oxidase A.
- 20 22. The method of claim 16 wherein said monoamine oxidase is monoamine oxidase B.
23. The method of claim 16 wherein said oxazolidinone is in a final concentration of from about 1 mM to about 1 nM.
- 25 24 The method of claim 16 wherein said MAO enzyme is sufficient to produce an absorbance change of 0.0005-0.05/minute at 421 nM.
25. The method of claim 16 wherein said substrate is in a concentration of from about 50 μ M to about 500 μ M.
- 30 26. The method of claim 16 wherein said assaying is performed in a spectrophotometer.
- 35 27. The method of claim 16 wherein said assaying is performed in a microtiterplate spectrophotometer.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/24526

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D413/10 A61K31/38 A61K31/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 09328 A (PHARMACIA & UPJOHN CO.) 13 March 1997 cited in the application see page 1, line 30 - page 3, line 31 see page 13, line 16 - line 21 see page 13, line 26 - line 35 see examples 49-51, 54, 55, 63-65 see page 95, formula 52 ---	1, 7, 10, 11
A	WO 97 30995 A (ZENECA LTD.) 28 August 1997 cited in the application see claims 1, 10, 11; tables A, B --- -/--	1, 7, 10, 11



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

24 March 1999

Date of mailing of the international search report

06/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/US 98/24526

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 352 781 A (E. I. DU PONT DE NEMOURS AND CO.) 31 January 1990 cited in the application see claims 1,11,12; examples; tables & US 4 948 801 A cited in the application & US 5 130 316 A cited in the application & US 5 254 577 A cited in the application ---	1,7,10, 11
A	WO 93 09103 A (THE UPJOHN CO.) 13 May 1993 cited in the application see abstract; claim 1 ---	1,7,10, 11
A	US 5 523 403 A (M. R. BARBACHYN) 4 June 1996 see column 40, line 13 - column 41, line 50; claim 1; table 1 -----	1,7,10, 11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/24526

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9709328 A	13-03-1997	AU 6718196 A CA 2228647 A CN 1197457 A CZ 9800493 A EP 0856002 A FI 980452 A NO 980855 A PL 325152 A	27-03-1997 13-03-1997 28-10-1998 12-08-1998 05-08-1998 27-02-1998 30-04-1998 06-07-1998
WO 9730995 A	28-08-1997	AU 1805397 A EP 0882042 A	10-09-1997 09-12-1998
EP 352781 A	31-01-1990	US 4948801 A AU 622465 B AU 3911589 A CA 1337526 A DK 374389 A FI 893618 A JP 2124877 A PT 91315 A US 5130316 A US 5043443 A US 5254577 A	14-08-1990 09-04-1992 01-02-1990 07-11-1995 30-01-1990 30-01-1990 14-05-1990 08-02-1990 14-07-1992 27-08-1991 19-10-1993
WO 9309103 A	13-05-1993	AT 146783 T AU 667198 B AU 2689892 A CA 2119556 A DE 69216251 D DE 69216251 T DK 610265 T EP 0610265 A GR 3022340 T JP 7500603 T US 5565571 A US 5801246 A US 5654428 A US 5756732 A US 5654435 A	15-01-1997 14-03-1996 07-06-1993 13-05-1993 06-02-1997 15-05-1997 09-06-1997 17-08-1994 30-04-1997 19-01-1995 15-10-1996 01-09-1998 05-08-1997 26-05-1998 05-08-1997
US 5523403 A	04-06-1996	AT 161833 T AU 670842 B AU 5323994 A CA 2147753 A CN 1092413 A CZ 9501366 A DE 69316240 D DE 69316240 T EP 0673370 A ES 2111188 T FI 952798 A GR 3026228 T HU 74099 A IL 107663 A JP 8504205 T MX 9307705 A NO 952253 A NZ 257031 A	15-01-1998 01-08-1996 04-07-1994 23-06-1994 21-09-1994 18-10-1995 12-02-1998 20-05-1998 27-09-1995 01-03-1998 07-06-1995 29-05-1998 28-11-1996 16-10-1996 07-05-1996 30-06-1994 08-08-1995 26-07-1996

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 98/24526

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5523403 A		PL 309283 A	02-10-1995
		SK 74695 A	11-10-1995
		WO 9413649 A	23-06-1994
		ZA 9307791 A	20-05-1995
